Quidel's Q4 Earnings Beat Street View Despite 21% Decline In Sales
- Oops!Something went wrong.Please try again later.
- QDEL
See more from Benzinga
Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices
FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.